5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
The S&P 500 recently sat just 2.5% below its all-time high. Look past the index, though, and the picture gets uglier.
GRAL - GRAIL Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$107.88
DETAILS
HIGH:
$175.00
LOW:
$56.00
MEDIAN:
$109.00
CONSENSUS:
$107.88
DOWNSIDE:
22.89%
Stock News
GRAIL to Announce Third Quarter 2026 Financial Results
SUNNYVALE, Calif., Oct. 21, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the third quarter 2026 following the close of market on Wednesday, Nov. 4, 2026.
GRAIL (NASDAQ:GRAL) Stock: Insider Joshua Ofman Sells 20,000 Shares
GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) CEO Joshua Ofman sold 20,000 shares of the firm's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $136.85, for a total value of $2,737,000.00. Following the transaction, the chief executive officer owned 342,271 shares in the company, valued at
GRAIL (NASDAQ:GRAL) Stock Price Down 5.6% on Insider Selling
GRAIL, Inc. (NASDAQ: GRAL - Get Free Report)'s stock price dropped 5.6% on Friday after an insider sold shares in the company. The stock traded as low as $129.03 and last traded at $127.9350. 67,481 shares traded hands during trading, a decline of 93% from the average session volume of 971,234 shares. The stock had previously
11 Stocks Most Likely to See a Short Squeeze Rally
Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into earnings season.
First-Class Amenity Kits Have Become Holy Grail Collectibles
For a rare breed of travel enthusiast, the free toiletry pouches are more than a throwaway convenience. They're a trip down memory lane.
Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore.
Grail's stock surged after a positive FDA panel vote. Insurer adoption is crucial for Galleri's success.
Head to Head Contrast: Gilead Sciences (NASDAQ:GILD) vs. GRAIL (NASDAQ:GRAL)
Gilead Sciences (NASDAQ: GILD - Get Free Report) and GRAIL (NASDAQ: GRAL - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation. Valuation and Earnings This table compares Gilead Sciences and
2 Growth Stocks to Buy in October
Grail and Veeva Systems could be well insulated from near-term headwinds.
Why CVS Is ‘Insanely Cheap,' ON Semi a Laggard Catching Up, and Grail Too Expensive to Chase
Jim Cramer sees three stocks with very different amounts of bad news or good news already baked into their prices, and figuring out which side each sits on changes everything about whether to buy.
GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026
GRAIL to Present Six Abstracts at the Early Detection of Cancer Conference (EDCC) Spanning Clinical Performance, Health Equity, and Real-World Implementation of Multi-Cancer Early Detection GRAIL to Present Two Abstracts at the European Society for Medical Oncology (ESMO) Congress, Across the Cancer Diagnostic Journey and Real-World Evidence SUNNYVALE, Calif., Oct. 5, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present additional data from both the NHS-Galleri trial and the PATHFINDER 2 study further evaluating the Galleri® multi-cancer early detection (MCED) test at the Early Detection of Cancer Conference (EDCC) in Edinburgh, the United Kingdom, taking place Oct. 6-8, 2026, and at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain taking place Oct. 23-27, 2026.
Grail Stock Has Skyrocketed 171% in 6 Months. Where Will It Be in 5 Years?
Adoption by insurers and FDA approval are critical for future performance. Profitability is not expected until 2032/2033, but revenue growth could be strong if adoption accelerates.
GRAIL (NASDAQ:GRAL) Shares Climb 5.5% – Time to Buy?
Shares of GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) rose 5.5% during mid-day trading on Wednesday. The stock traded as high as $141.97 and last traded at $144.0280. Approximately 113,792 shares were traded during trading, a decline of 88% from the average daily volume of 962,223 shares. The stock had previously closed at $136.57. Analyst
GRAIL (NASDAQ:GRAL) Hits New 12-Month High – Should You Buy?
Shares of GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) hit a new 52-week high on Thursday. The company traded as high as $151.46 and last traded at $140.12, with a volume of 1920136 shares trading hands. The stock had previously closed at $136.57. Wall Street Analysts Forecast Growth Several equities research analysts recently issued reports
3 Reasons to Buy Grail (GRAL) Hand Over Fist in October
Grail's stock recently hit its all-time high. If the FDA approves Galleri, it still looks reasonably valued.
Grail Stock Has Soared 180% in 6 Months. Here's Why the Stock Has More Room to Run.
The key to the company's future is medical insurers adopting Galleri. The FDA looks likely to grant pre-market approval for Galleri following this week's vote.
Insider Selling: GRAIL (NASDAQ:GRAL) CFO Sells $382,694.00 in Stock
GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) CFO Aaron Freidin sold 4,100 shares of the company's stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $93.34, for a total transaction of $382,694.00. Following the transaction, the chief financial officer owned 248,983 shares in the company,
Here's Why Grail Stock Surged 55% This Week
Grail's stock surged 55% after a favorable FDA committee vote, and ultimately, FDA approval could drive insurer adoption and broader market access. Galleri's efficacy vote was close, reflecting ongoing concerns about effectiveness.
GRAIL (NASDAQ:GRAL) CEO Joshua Ofman Sells 61,452 Shares
GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) CEO Joshua Ofman sold 61,452 shares of the firm's stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $97.74, for a total transaction of $6,006,318.48. Following the sale, the chief executive officer owned 362,271 shares of the company's stock, valued
Owning a Home Is Seen as a Financial Holy Grail. But What If It Isn't?
There are many unrecognized trade-offs to home ownership that can make renting a better economic choice.
Price Targets
Grail price target raised to $120 from $60 at Morgan Stanley
$120.00
(was $139.41)
Morgan Stanley
Grail price target raised to $175 from $105 at UBS
$175.00
(was $137.72)
UBS
Grail price target raised to $150 from $80 at Canaccord
$150.00
(was $126.89)
Kyle Mikson
·
Canaccord Genuity
GRAIL, Inc. (GRAL) PT Raised to $100 at Mizuho
$100.00
(was $125.21)
Bradley Bowers
·
Mizuho Securities
Grail price target raised to $118 from $86 at Baird
$118.00
(was $107.97)
Robert Bamberger
·
Robert W. Baird
Grail initiated with a Sector Perform at RBC Capital
$84.00
(was $75.11)
UBS
RBC Capital Starts GRAIL, Inc. (GRAL) at Sector Perform
$84.00
(was $75.11)
Dan Leonard
·
RBC Capital
Grail initiated with a Buy at UBS
$105.00
(was $79.10)
UBS
Grail price target raised to $65 from $58 at Mizuho
$65.00
(was $73.12)
Mizuho Securities
Goldman Sachs Starts GRAIL, Inc. (GRAL) at Neutral
$60.00
(was $66.55)
Evie Koslosky
·
Goldman Sachs
Grail price target raised to $56 from $54 at Piper Sandler
$56.00
(was $54.40)
Piper Sandler
Grail price target lowered to $70 from $82 at Baird
$70.00
(was $54.40)
Robert W. Baird
Grail initiated with a Neutral at Mizuho
$58.00
(was $45.76)
Bradley Bowers
·
Mizuho Securities
Grail initiated with a Neutral at Piper Sandler
$54.00
(was $45.76)
Piper Sandler
Grail price target lowered to $60 from $110 at Morgan Stanley
$60.00
(was $43.03)
Kallum Titchmarsh
·
Morgan Stanley
Grail price target lowered to $82 from $113 at Baird
$82.00
(was $101.53)
Catherine Ramsey Schulte
·
Robert W. Baird
Grail price target lowered to $80 from $105 at Canaccord
$80.00
(was $101.53)
Canaccord Genuity
Grail initiated with an Outperform at Baird
$113.00
(was $97.50)
Robert W. Baird
Grail price target raised to $130 from $100 at Guggenheim
$130.00
(was $107.58)
Guggenheim
Grail assumed with an Equal Weight at Morgan Stanley
$110.00
(was $98.27)
Morgan Stanley